Indian Pharma Industry
- All
- News
- Videos
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Indian Pharmaceutical Industry Transformed By GST Reforms And Research Development In 2025
With GST reforms and Research Development Incentive (RDI) Scheme, the year 2025 has been a crucial turning point for Indian pharma, said industry experts on Thursday.
-
Pharma OTT Release: When, Where to Watch the Malayalam Medical Thriller Web Series
The series shows the conspiracy of unethical drug selling in which many high stake people are involved. It is a suspenseful story with lots of twists and turns and it stars with Nivin Pauly and other effective supporting roles.Pharma is an Indian techno-thriller that uncovers the shadowy world of medicine, morality and massive pharmaceutical power.
-
Who Is Rama Raju Mantena? The Indian-American Pharma Titan Behind Viral Udaipur Wedding
Rama Raju Mantena is a prominent figure in the US pharmaceutical industry, serving as the Chairman and CEO of Ingenus Pharmaceuticals, a company with operations in the US, Switzerland, and India.
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
Expand Export Markets, Boost Local Demand: India's Plan For Trump Tariffs
Faced with the United States' 50 per cent tariff on exports, India has reached out to dozens of nations to up trade in key sectors like textiles and chemicals. The goal - offset a potential $48 billion loss in export of goods and services to the US.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Indian Pharmaceutical Industry Transformed By GST Reforms And Research Development In 2025
With GST reforms and Research Development Incentive (RDI) Scheme, the year 2025 has been a crucial turning point for Indian pharma, said industry experts on Thursday.
-
Pharma OTT Release: When, Where to Watch the Malayalam Medical Thriller Web Series
The series shows the conspiracy of unethical drug selling in which many high stake people are involved. It is a suspenseful story with lots of twists and turns and it stars with Nivin Pauly and other effective supporting roles.Pharma is an Indian techno-thriller that uncovers the shadowy world of medicine, morality and massive pharmaceutical power.
-
Who Is Rama Raju Mantena? The Indian-American Pharma Titan Behind Viral Udaipur Wedding
Rama Raju Mantena is a prominent figure in the US pharmaceutical industry, serving as the Chairman and CEO of Ingenus Pharmaceuticals, a company with operations in the US, Switzerland, and India.
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
Expand Export Markets, Boost Local Demand: India's Plan For Trump Tariffs
Faced with the United States' 50 per cent tariff on exports, India has reached out to dozens of nations to up trade in key sectors like textiles and chemicals. The goal - offset a potential $48 billion loss in export of goods and services to the US.
